In 536 immunocompetent adults aged 50+ given a fifth or later COVID-19 booster, all seven licensed vaccines boosted antibodies, peaking at day 28 and near baseline by day 365; responses were higher in those primed with BNT162b2 than AZD1222.
RCTn = 536
C et al. The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults